Advertisement
Advertisement
U.S. markets open in 3 hours 36 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Natera, Inc. (NTRA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
55.17+1.58 (+2.95%)
At close: 04:00PM EDT
55.17 0.00 (0.00%)
Pre-Market: 04:00AM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Relative Strength Index (RSI)

Relative Strength Index (RSI)

Previous Close53.59
Open54.21
Bid0.00 x 1100
Ask0.00 x 800
Day's Range53.49 - 56.44
52 Week Range26.10 - 129.09
Volume1,287,542
Avg. Volume1,339,579
Market Cap5.349B
Beta (5Y Monthly)1.33
PE Ratio (TTM)N/A
EPS (TTM)-5.89
Earnings DateNov 02, 2022 - Nov 07, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est84.91
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for NTRA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Natera, Inc.
    Analyst Report: Illumina, Inc.Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina’s high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
    Rating
    Fair Value
    Economic Moat
    3 days agoMorningstar
View more
  • PR Newswire

    Natera Announces Enrollment Completion for RenaCARE Study

    Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced full enrollment for the RenaCARE (Renasight Clinical Application, Review and Evaluation) study, a real world, prospective, multi-center clinical study to assess the clinical utility of Natera's Renasight™ genetic testing panel, which analyzes more than 380 genes related to kidney disease. Enrollment in the study was completed early as a result of statistically meaningful interim data analysis. The study includ

  • PR Newswire

    Natera Announces Q-Sub Filing with FDA for its Panorama® NIPT

    Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, announced earlier today at the Canaccord Genuity 42nd Annual Growth Conference in Boston that the company has proactively filed a pre-submission to the FDA for its Panorama® non-invasive prenatal test (NIPT) as part of the Q-Sub process. The company filed its pre-submission in June 2022 for fetal chromosomal aneuploidies and for 22q11.2 deletion syndrome.

  • Zacks

    Natera (NTRA) Reports Q2 Loss, Tops Revenue Estimates

    Natera (NTRA) delivered earnings and revenue surprises of -2.04% and 2.11%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Advertisement
Advertisement